title: Neurocysticercosis in a patient in Canada.
authors.affiliation: Epilepsy Programme, University of Western Ontario, London Health Sciences Centre, Rm. B10-118, 339 Windermere Rd., London ON N6A 5A5. jorge.burneo@lhsc.on.ca [corrected]
authors.forename: Jorge G
authors.initials: JG
authors.lastname: Burneo
authors.forename: Ian
authors.initials: I
authors.lastname: Plener
authors.forename: Hector H
authors.initials: HH
authors.lastname: Garcia
mesh_terms: D015766:Albendazole / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D001927:Brain Diseases / Q000175:diagnosis* / Q000628:therapy; D002170:Canada; D003907:Dexamethasone / Q000627:therapeutic use; D006801:Humans; D007964:Leukocytosis / Q000209:etiology; D008279:Magnetic Resonance Imaging; D008297:Male; D008800:Mexico / Q000208:ethnology; D008875:Middle Aged; D020019:Neurocysticercosis / Q000175:diagnosis* / Q000628:therapy; D010672:Phenytoin / Q000627:therapeutic use; D012640:Seizures / Q000188:drug therapy / Q000209:etiology*; D014195:Travel
chemical_list: D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D000981:Antiprotozoal Agents; D010672:Phenytoin; D003907:Dexamethasone; D015766:Albendazole